AIDS InfoNet Logo
This website is certified by Health On the Net Foundation. Click to verify.
This site complies with the HONcode standard for trustworthy health information:
verify here.

The Henry J. Kaiser Family Foundation
Site of the Week
November 2003

The Health Leader Award 2006
The Health Leader Award 2006

The HOPE Reward Medical Award Featured Site Award

IBS Tales Hope Award Editor's Choice Award

Listed in Listed in Treasures of the Internet

AIDS InfoNet Logo.  The AIDS InfoNet - Reliable, Up-to-Date AIDS Treatment Information
International Association of Providers of AIDS Care
Reviewed June 7, 2016

Fact Sheet 450

Darunavir (Prezista)



Darunavir is a drug used as part of antiretroviral therapy (ART). It is also called Prezista. It is manufactured by Janssen Therapeutics.

Darunavir is a protease inhibitor. These drugs prevent the protease enzyme from working. HIV protease acts like a chemical scissors. It cuts the raw material for HIV into specific pieces needed to build a new virus. Protease inhibitors “gum up” these scissors.



Darunavir was approved in 2006 as an antiretroviral drug (ARV) for people with HIV infection, aged 3 or older. 

While antiretroviral therapy (ART) is recommended for all people living with HIV, independent of your symptoms or CD4 count, you and your health care provider should consider your CD4 cell count, your viral load, any symptoms you are having, and your attitude about taking ART. Fact Sheet 404 has more information about guidelines for the use of ART.

If you take darunavir with other ARVs, you can reduce your viral load to extremely low levels, and increase your CD4 cell counts. This should mean staying healthier longer.



Many new copies of HIV have mutations. They are slightly different from the original virus. Some mutations can keep multiplying even when you are taking an ARV. When this happens, the drug will stop working. This is called “developing resistance” to the drug. See Fact Sheet 126 for more information on resistance.

Sometimes, if your virus develops resistance to one drug, it will also have resistance to other ARVs. This is called “cross-resistance.” Resistance can develop quickly. It is very important to take ARVs according to instructions, on schedule, and not to skip or reduce doses.

Darunavir was specifically developed to control HIV that is already resistant to some other protease inhibitors. It has shown low levels of cross-resistance to other protease inhibitors.



Darunavir is taken by mouth as a tablet. The normal adult dose is 600 milligrams (mg) taken with one 100 mg capsule of ritonavir, two times a day.

In 2008, the FDA approved darunavir for use as an initial treatment regimen for people with HIV. This regimen is 800 mg (two 400 mg tablets) taken with ritonavir 100 mg once daily, with food. In 2010, this once-daily dosing pattern was approved for treatment-experienced patients (those who have been taking ART for some time), whose virus does not have any darunavir resistance mutations.

A combination medication of darunavir and 150 mg of the newer booster cobicistat, called Prezcobix is now available (see fact sheet 451). This medication is dosed one tablet, once daily.

Darunavir is also approved for children ages 3 years old or older who have already used ART. There are 75 mg and 150 mg tablets. A liquid formulation is approved for use in adults or children at least 6 years old. It is used with ritonavir. Dose is based on patient weight.

Darunavir should be taken with food. This increases blood levels of darunavir.  The type of food does not matter.

Darunavir should be stored at room temperature.



The most common side effects include diarrhea, nausea, headache, and a common cold. Some people may get a skin rash. In rare cases, this could be serious.

Darunavir has not been carefully studied in patients with hepatitis B or hepatitis C, or people with existing liver disease. Their condition should be carefully monitored. Some cases of severe liver damage have been reported.

Darunavir taken with ritonavir can cause increases in cholesterol and triglycerides (blood fats). See Fact Sheet 123 for more information on blood fats. High levels of blood fats can increase the risk of heart disease. Be sure that your health care provider checks your blood fat levels before you start taking darunavir, and regularly after that.

Darunavir is a sulfa drug. If you are allergic to sulfa drugs, be sure to tell your health care provider, as some people who are allergic to sulfa may also be allergic to darunavir.



Darunavir with ritonavir can interact with other drugs or supplements that you are taking. These interactions can change the amount of each drug in your bloodstream and cause an under- or overdose. New interactions are being identified all the time.

Drugs to watch out for include other ARVs, drugs to treat tuberculosis (see fact sheet 518), for erectile dysfunction (such as Viagra), antidepressants, drugs for heart rhythm (antiarrhythmics), and for migraine headaches. Interactions are also possible with several antihistamines (allergy medications), sedatives, drugs to lower cholesterol, and anti-fungal drugs.

Make sure that your health care provider knows about ALL drugs and supplements you are taking.

  • Some birth control pills may not work if you are taking darunavir. Talk to your health care provider about how to prevent an unwanted pregnancy.
  • Darunavir lowers blood levels of methadone. Watch for signs of excessive sedation if you take darunavir with buprenorphine.
  • The herb St. John's Wort (See Fact Sheet 729) lowers the blood levels of some protease inhibitors. Do not take it while taking darunavir.



Back to Fact Sheet Categories

International Association of Providers of AIDS Care


The AIDS InfoNet is a project of the International Association of Providers of AIDS Care.


United States National Library of Medicine

Partially funded by the National Library of Medicine

Search Our Site
Newest Fact Sheets
Print This Fact Sheet
You can print this fact sheet on a single page in Microsoft Word (.doc) format or Adobe Acrobat (.pdf) format. Click on the links below to open the document in your browser and then print it.
 Adobe Acrobat PDF
 Microsoft Word

You can print directly from your browser using the link below. The printout will probably go onto a second page.
 Print Version (Web)

Monthly E-mail Updates

The InfoNet updates its Fact Sheets frequently. A listing of each month's changes is posted to several e-mail lists.

If you would like to receive this monthly update by personal e-mail, please click on the SUBMIT button.